332 related articles for article (PubMed ID: 21795476)
1. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Kummar S; Chen A; Ji J; Zhang Y; Reid JM; Ames M; Jia L; Weil M; Speranza G; Murgo AJ; Kinders R; Wang L; Parchment RE; Carter J; Stotler H; Rubinstein L; Hollingshead M; Melillo G; Pommier Y; Bonner W; Tomaszewski JE; Doroshow JH
Cancer Res; 2011 Sep; 71(17):5626-34. PubMed ID: 21795476
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Kummar S; Ji J; Morgan R; Lenz HJ; Puhalla SL; Belani CP; Gandara DR; Allen D; Kiesel B; Beumer JH; Newman EM; Rubinstein L; Chen A; Zhang Y; Wang L; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
Clin Cancer Res; 2012 Mar; 18(6):1726-34. PubMed ID: 22307137
[TBL] [Abstract][Full Text] [Related]
3. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
LoRusso PM; Li J; Burger A; Heilbrun LK; Sausville EA; Boerner SA; Smith D; Pilat MJ; Zhang J; Tolaney SM; Cleary JM; Chen AP; Rubinstein L; Boerner JL; Bowditch A; Cai D; Bell T; Wolanski A; Marrero AM; Zhang Y; Ji J; Ferry-Galow K; Kinders RJ; Parchment RE; Shapiro GI
Clin Cancer Res; 2016 Jul; 22(13):3227-37. PubMed ID: 26842236
[TBL] [Abstract][Full Text] [Related]
4. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Wahner Hendrickson AE; Menefee ME; Hartmann LC; Long HJ; Northfelt DW; Reid JM; Boakye-Agyeman F; Kayode O; Flatten KS; Harrell MI; Swisher EM; Poirier GG; Satele D; Allred J; Lensing JL; Chen A; Ji J; Zang Y; Erlichman C; Haluska P; Kaufmann SH
Clin Cancer Res; 2018 Feb; 24(4):744-752. PubMed ID: 29138343
[No Abstract] [Full Text] [Related]
5. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Samol J; Ranson M; Scott E; Macpherson E; Carmichael J; Thomas A; Cassidy J
Invest New Drugs; 2012 Aug; 30(4):1493-500. PubMed ID: 21590367
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.
Su JM; Thompson P; Adesina A; Li XN; Kilburn L; Onar-Thomas A; Kocak M; Chyla B; McKeegan E; Warren KE; Goldman S; Pollack IF; Fouladi M; Chen A; Giranda V; Boyett J; Kun L; Blaney SM
Neuro Oncol; 2014 Dec; 16(12):1661-8. PubMed ID: 24908656
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
Tan AR; Chan N; Kiesel BF; Stein MN; Moss RA; Malhotra J; Aisner J; Shah M; Gounder M; Lin H; Kane MP; Lin Y; Ji J; Chen A; Beumer JH; Mehnert JM
Cancer Chemother Pharmacol; 2022 Jan; 89(1):49-58. PubMed ID: 34669023
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.
Pratz KW; Rudek MA; Gojo I; Litzow MR; McDevitt MA; Ji J; Karnitz LM; Herman JG; Kinders RJ; Smith BD; Gore SD; Carraway HE; Showel MM; Gladstone DE; Levis MJ; Tsai HL; Rosner G; Chen A; Kaufmann SH; Karp JE
Clin Cancer Res; 2017 Feb; 23(4):899-907. PubMed ID: 27551000
[No Abstract] [Full Text] [Related]
10. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
[TBL] [Abstract][Full Text] [Related]
11. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
Ji J; Kinders RJ; Zhang Y; Rubinstein L; Kummar S; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2011; 6(10):e26152. PubMed ID: 22028822
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells.
Zhang YW; Regairaz M; Seiler JA; Agama KK; Doroshow JH; Pommier Y
Nucleic Acids Res; 2011 May; 39(9):3607-20. PubMed ID: 21227924
[TBL] [Abstract][Full Text] [Related]
13. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Yang SX; Kummar S; Steinberg SM; Murgo AJ; Gutierrez M; Rubinstein L; Nguyen D; Kaur G; Chen AP; Giranda VL; Tomaszewski JE; Doroshow JH;
Cancer Biol Ther; 2009 Nov; 8(21):2004-9. PubMed ID: 19823047
[TBL] [Abstract][Full Text] [Related]
15. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
16. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Niu J; Scheuerell C; Mehrotra S; Karan S; Puhalla S; Kiesel BF; Ji J; Chu E; Gopalakrishnan M; Ivaturi V; Gobburu J; Beumer JH
J Clin Pharmacol; 2017 Aug; 57(8):977-987. PubMed ID: 28387939
[TBL] [Abstract][Full Text] [Related]
17. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
19. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.
Kummar S; Raffeld M; Juwara L; Horneffer Y; Strassberger A; Allen D; Steinberg SM; Rapisarda A; Spencer SD; Figg WD; Chen X; Turkbey IB; Choyke P; Murgo AJ; Doroshow JH; Melillo G
Clin Cancer Res; 2011 Aug; 17(15):5123-31. PubMed ID: 21673063
[TBL] [Abstract][Full Text] [Related]
20. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.
Kummar S; Kinders R; Gutierrez ME; Rubinstein L; Parchment RE; Phillips LR; Ji J; Monks A; Low JA; Chen A; Murgo AJ; Collins J; Steinberg SM; Eliopoulos H; Giranda VL; Gordon G; Helman L; Wiltrout R; Tomaszewski JE; Doroshow JH
J Clin Oncol; 2009 Jun; 27(16):2705-11. PubMed ID: 19364967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
